Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript
PresentationLee RothBurns McClellan, Inc. Thanks, operator. As a reminder, a press release summarizing the results of the trial can be found on the Investor Relations section of the company's website. This call is also being recorded, and a copy of the slides and audio will be posted to the IR site at the conclusion of the live event. Following some prepared remarks from management, we'll open the call to your questions. Before we begin, I'd like to remind everyone that remarks about future expectations, pl ...